NO330896B1 - Nukleinsyre som koder for en mutert form av h-parkin, polypeptid, antistoff,sammensetning, probe, fremgangsmater, vektor, celle, ikke-humant pattedyr samt anvendelser. - Google Patents
Nukleinsyre som koder for en mutert form av h-parkin, polypeptid, antistoff,sammensetning, probe, fremgangsmater, vektor, celle, ikke-humant pattedyr samt anvendelser. Download PDFInfo
- Publication number
- NO330896B1 NO330896B1 NO20012342A NO20012342A NO330896B1 NO 330896 B1 NO330896 B1 NO 330896B1 NO 20012342 A NO20012342 A NO 20012342A NO 20012342 A NO20012342 A NO 20012342A NO 330896 B1 NO330896 B1 NO 330896B1
- Authority
- NO
- Norway
- Prior art keywords
- parkin
- gene
- exons
- nucleic acid
- mutation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 51
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 35
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 35
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 35
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 16
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 16
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 16
- 239000013598 vector Substances 0.000 title claims abstract description 12
- 239000000523 sample Substances 0.000 title claims description 59
- 239000000203 mixture Substances 0.000 title claims description 6
- 230000035772 mutation Effects 0.000 claims abstract description 124
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 claims abstract description 79
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 102000045222 parkin Human genes 0.000 claims abstract description 30
- 230000000694 effects Effects 0.000 claims abstract description 9
- 208000027089 Parkinsonian disease Diseases 0.000 claims abstract description 8
- 230000004077 genetic alteration Effects 0.000 claims abstract description 8
- 231100000118 genetic alteration Toxicity 0.000 claims abstract description 8
- 108700007244 parkin Proteins 0.000 claims abstract description 8
- 230000004075 alteration Effects 0.000 claims abstract 3
- 238000001514 detection method Methods 0.000 claims description 34
- 230000008859 change Effects 0.000 claims description 31
- 230000003321 amplification Effects 0.000 claims description 28
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 238000007403 mPCR Methods 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 102200002496 rs34424986 Human genes 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 5
- 238000012163 sequencing technique Methods 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 2
- 108700024394 Exon Proteins 0.000 abstract description 88
- 238000012217 deletion Methods 0.000 abstract description 86
- 230000037430 deletion Effects 0.000 abstract description 86
- 206010034010 Parkinsonism Diseases 0.000 abstract description 9
- 238000003780 insertion Methods 0.000 abstract description 5
- 230000037431 insertion Effects 0.000 abstract description 5
- 108020004711 Nucleic Acid Probes Proteins 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000002853 nucleic acid probe Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 description 25
- 102000053602 DNA Human genes 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 24
- 108091034117 Oligonucleotide Proteins 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 102100022207 E3 ubiquitin-protein ligase parkin Human genes 0.000 description 7
- 208000018737 Parkinson disease Diseases 0.000 description 7
- 239000002131 composite material Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 230000001364 causal effect Effects 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000014094 Dystonic disease Diseases 0.000 description 3
- 102220641846 E3 ubiquitin-protein ligase parkin_C289G_mutation Human genes 0.000 description 3
- 108010071690 Prealbumin Proteins 0.000 description 3
- 208000010118 dystonia Diseases 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102220261130 rs148851677 Human genes 0.000 description 3
- 102200001024 rs199657839 Human genes 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 102220474645 HLA class II histocompatibility antigen, DP alpha 1 chain_W74C_mutation Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 102000009190 Transthyretin Human genes 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 102200002497 c.838G>A Human genes 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007498 myristoylation Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 102200001039 rs1801334 Human genes 0.000 description 2
- 102200001038 rs1801582 Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102220551876 Cellular tumor antigen p53_P223S_mutation Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102220641842 E3 ubiquitin-protein ligase parkin_G328E_mutation Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101001000631 Homo sapiens Peripheral myelin protein 22 Proteins 0.000 description 1
- 101001082860 Homo sapiens Peroxisomal membrane protein 2 Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 208000028281 autosomal inheritance Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 102200002489 c.766C>T Human genes 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 208000019479 dysautonomia Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 208000018290 primary dysautonomia Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
- C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9814524A FR2786199B1 (fr) | 1998-11-19 | 1998-11-19 | Mutations du gene de la parkine, compositions, methodes et utilisations |
| US12423999P | 1999-03-12 | 1999-03-12 | |
| FR9910140A FR2797272B1 (fr) | 1999-08-04 | 1999-08-04 | Nouvelles mutations du gene de la parkine, compositions, methodes et utilisations |
| PCT/FR1999/002833 WO2000031253A2 (fr) | 1998-11-19 | 1999-11-18 | Mutations du gene de la parkine, compositions, methodes et utilisations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20012342D0 NO20012342D0 (no) | 2001-05-11 |
| NO20012342L NO20012342L (no) | 2001-07-18 |
| NO330896B1 true NO330896B1 (no) | 2011-08-08 |
Family
ID=27253486
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20012342A NO330896B1 (no) | 1998-11-19 | 2001-05-11 | Nukleinsyre som koder for en mutert form av h-parkin, polypeptid, antistoff,sammensetning, probe, fremgangsmater, vektor, celle, ikke-humant pattedyr samt anvendelser. |
| NO20110577A NO332174B1 (no) | 1998-11-19 | 2011-04-14 | Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse |
| NO20110582A NO333907B1 (no) | 1998-11-19 | 2011-04-14 | Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse. |
| NO20110578A NO332173B1 (no) | 1998-11-19 | 2011-04-14 | Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse. |
| NO20110580A NO333906B1 (no) | 1998-11-19 | 2011-04-14 | Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20110577A NO332174B1 (no) | 1998-11-19 | 2011-04-14 | Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse |
| NO20110582A NO333907B1 (no) | 1998-11-19 | 2011-04-14 | Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse. |
| NO20110578A NO332173B1 (no) | 1998-11-19 | 2011-04-14 | Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse. |
| NO20110580A NO333906B1 (no) | 1998-11-19 | 2011-04-14 | Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8835618B2 (el) |
| EP (5) | EP2128257A3 (el) |
| JP (1) | JP5424519B2 (el) |
| AT (1) | ATE440138T1 (el) |
| AU (1) | AU778281B2 (el) |
| CA (1) | CA2351567C (el) |
| CY (1) | CY1110535T1 (el) |
| DE (1) | DE69941300D1 (el) |
| DK (1) | DK1131424T3 (el) |
| ES (1) | ES2330281T3 (el) |
| IL (3) | IL142755A0 (el) |
| NO (5) | NO330896B1 (el) |
| NZ (1) | NZ512313A (el) |
| PT (1) | PT1131424E (el) |
| WO (1) | WO2000031253A2 (el) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1081225A1 (en) * | 1999-08-30 | 2001-03-07 | Biofrontera Pharmaceuticals GmbH | Transgenic animal model for neurodegenerative diseases |
| US20040248092A1 (en) * | 2000-05-26 | 2004-12-09 | Vance Jeffrey M | Methods of screening for parkinsons's disease |
| FR2845245A1 (fr) * | 2002-10-07 | 2004-04-09 | Aventis Pharma Sa | Modele animal de la maladie de parkinson |
| US7790390B2 (en) | 2004-10-27 | 2010-09-07 | Duke University | Methods for identifying an individual at increased risk of developing coronary artery disease |
| US7807465B2 (en) | 2004-10-27 | 2010-10-05 | Duke University | Methods for identifying an individual at increased risk of developing coronary artery disease |
| CN110295147A (zh) * | 2019-07-22 | 2019-10-01 | 新乡医学院 | 一种食管癌细胞系中功能基因敲除后增殖表型的快速鉴定方法及其应用 |
| WO2021237158A1 (en) * | 2020-05-21 | 2021-11-25 | Nysnobio Gt, Llc | Gene therapy delivery of parkin mutants having increased activity to treat parkinson's disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0672753B1 (en) * | 1993-10-05 | 2008-01-02 | Asahi Glass Company Ltd. | Multicloning vector, expression vector, and production of foreign protein with expression vector |
| WO1996039535A1 (en) | 1995-06-06 | 1996-12-12 | Jan Vijg | Method of and apparatus for diagnostic dna testing |
| US6716621B1 (en) | 1998-02-09 | 2004-04-06 | Boehringer Ingelheim International Gmbh | Isolated DNA or gene responsible for Parkinson's disease |
| CA2872581C (fr) * | 1998-11-19 | 2018-04-10 | Aventis Pharma S.A. | Mutations du gene de la parkine, compositions, methodes et utilisations |
-
1999
- 1999-11-18 EP EP09167384A patent/EP2128257A3/fr not_active Withdrawn
- 1999-11-18 AU AU12769/00A patent/AU778281B2/en not_active Ceased
- 1999-11-18 PT PT99956079T patent/PT1131424E/pt unknown
- 1999-11-18 IL IL14275599A patent/IL142755A0/xx unknown
- 1999-11-18 JP JP2000584062A patent/JP5424519B2/ja not_active Expired - Lifetime
- 1999-11-18 DE DE69941300T patent/DE69941300D1/de not_active Expired - Lifetime
- 1999-11-18 AT AT99956079T patent/ATE440138T1/de active
- 1999-11-18 EP EP10184008A patent/EP2345722A1/fr not_active Withdrawn
- 1999-11-18 NZ NZ512313A patent/NZ512313A/en not_active IP Right Cessation
- 1999-11-18 DK DK99956079T patent/DK1131424T3/da active
- 1999-11-18 WO PCT/FR1999/002833 patent/WO2000031253A2/fr active Application Filing
- 1999-11-18 EP EP99956079A patent/EP1131424B1/fr not_active Expired - Lifetime
- 1999-11-18 ES ES99956079T patent/ES2330281T3/es not_active Expired - Lifetime
- 1999-11-18 CA CA2351567A patent/CA2351567C/fr not_active Expired - Lifetime
- 1999-11-18 EP EP10184042A patent/EP2305816A1/fr not_active Withdrawn
- 1999-11-18 EP EP10184027A patent/EP2311954A1/fr not_active Withdrawn
-
2001
- 2001-04-23 IL IL142755A patent/IL142755A/en not_active IP Right Cessation
- 2001-05-11 NO NO20012342A patent/NO330896B1/no not_active IP Right Cessation
-
2007
- 2007-11-26 IL IL187652A patent/IL187652A/en not_active IP Right Cessation
-
2009
- 2009-11-11 CY CY20091101178T patent/CY1110535T1/el unknown
-
2011
- 2011-04-14 NO NO20110577A patent/NO332174B1/no not_active IP Right Cessation
- 2011-04-14 NO NO20110582A patent/NO333907B1/no not_active IP Right Cessation
- 2011-04-14 NO NO20110578A patent/NO332173B1/no not_active IP Right Cessation
- 2011-04-14 NO NO20110580A patent/NO333906B1/no not_active IP Right Cessation
- 2011-08-15 US US13/209,495 patent/US8835618B2/en not_active Expired - Fee Related
-
2014
- 2014-08-07 US US14/454,026 patent/US9540693B2/en not_active Expired - Fee Related
-
2016
- 2016-11-04 US US15/343,323 patent/US20170183736A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9540693B2 (en) | Mutations of the parkin gene, compositions, methods and uses | |
| EP0920534B1 (en) | Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (hnf) hnf-1alpha, hnf-1beta and hnf-4alpha | |
| NO20100798L (no) | Polymorfismer i det humane MDR-1-genet og deres diagnostiske og terapeutiske anvendelse | |
| US6660476B2 (en) | Polymorphisms in the PNMT gene | |
| EP1625231A1 (en) | Diagnosis and prediction of parkinson's disease | |
| US6153386A (en) | Method to determine predisposition to hypertension | |
| US7998667B1 (en) | Mutations of the parkin gene, compositions, methods and uses | |
| US20070154935A1 (en) | Human obesity susceptibility gene and uses thereof | |
| AU743778B2 (en) | Disease association by locus stratification | |
| EP1283889A1 (en) | Mutated eukariotic translation initiation factor 2 alpha kinase 3, eif2ak3, in patients with neonatal insulin-dependent diabetes and multiple epiphyseal dysplasia (wolcott-rallison syndrome) | |
| WO2005071104A1 (en) | Assay for bipolar affective disorder | |
| Arngrimsson | PREDISPOSITION TO HYPERTENSION | |
| FR2786199A1 (fr) | Mutations du gene de la parkine, compositions, methodes et utilisations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |